Skip Navigation

Link to  the National Institutes of Health  
The Science of Drug Abuse and Addiction from the National Institute on Drug Abuse Archives of the National Institute on Drug Abuse web site
Go to the Home page
   

NIDA Home > Publications > Director's Reports > September, 2009 Index    

Director's Report to the National Advisory Council on Drug Abuse - September, 2009



Extramural Policy and Review Activities

Receipt, Referral, and Review

NIDA received 2,868 applications, including both primary and dual assignments, for which the Office of Extramural Affairs (OEA) managed the programmatic referral process during this Council cycle. Of these, NIDA received the primary assignment on 2,005 applications, including 580 Challenge Grant Applications (RC1) and 127 Grand Opportunity Grant Applications (RC2).

OEA arranged and managed 37 grant review meetings in which 737 applications were evaluated. OEA's reviews included applications in chartered, standing review committees and Special Emphasis Panels (SEPs). In addition, OEA's Contracts Review Branch (CRB) arranged and managed 18 contract proposal review meetings.

NIDA's chartered committees consist of NIDA-E (Treatment Review Committee), NIDA-F (Health Services Review Committee), NIDA-L (Medications Development Committee), and NIDA-K (Training Committee). In addition to meetings of each of these committees, OEA staff held 33 Special Emphasis Panels to review grant applications for a variety of reasons:

  • Recovery Act Limited Competitions for NIH Grants (RC2 & P30)
  • Conflicts with the chartered committees
  • Program Project grant applications
  • Cutting-Edge Basic Research Awards (CEBRA)
  • Behavioral Science Track Award for Rapid Transition (B/START)
  • Imaging Science Track Award for Research Transition (I/START)
  • Conference Grants (R13)
  • Mechanism for Time-Sensitive Research Opportunities
  • Requests for Applications (RFAs)
  • Loan Repayment Program

OEA managed the following RFA reviews:

  • OD09-004 - Recovery Act Limited Competition for NIH Grants: Research and Research Infrastructure Grand Opportunities (RC2)
  • OD09-005 - Recovery Act Limited Competition: Biomedical Research Core Centers to Enhance Research Resources (P30)
  • DA09-008/009 - Brain Imaging Studies of Negative Reinforcement in Humans (R01 & R21)
  • DA09-011 - 2009 NIDA Avant-Garde Award Program for HIV/AIDS Research (DP1)
  • DA09-012 - Exploratory Centers for Translational Research on the Clinical Neurobiology of Drug Addiction (P20)
  • DA09-013/014 - Interactions Between Physical Activity and Drug Abuse (R01& R03)
  • DA09-015 - The Mouse Gene Development Initiative (R01)
  • DA09-016 - Behavioral Pharmacology and Genetics: Translating and Targeting Individual Differences (R03)
  • DA09-020 - Secondary Data Analyses for Substance Abuse Research (R21/R33)
  • DA09-022 - Biosignatures of Chronic Drug Exposure (R21)

Completed contract-related review activity from the Contracts Review Branch since the last Council includes:

R&D and non-R&D Contract Reviews

  • NO1DA-9-2217 - NIDA Center for Genetic Studies
  • N01DA-9-8882 - Drug Testing for Clinical Trials
  • N01DA-9-8891 - In Vitro Metabolism
  • N01DA-9-1139 - Communications Support
  • N01DA-9-1141 - Media Support
  • N01DA-10-7772 - Preparation and Distribution of Research Drug Products

Phase II SBIR Contract Reviews

  • N44DA-9-8874 - Novel Azetidine CB1 Antagonists
  • N44DA-9-8869 - Long Acting Buprenorphine for Opiate Maintenance

Phase I SBIR Contract Reviews

  • N43DA-10-1205 - International Activities
  • N43DA-10-2218 - New Technologies: Integrating Data from Prescription Monitoring Program(s) to Current Clinical Practice
  • N43DA-10-2219 - Development of Innovative Techniques/Tools for the Screening, Recruitment and Follow-up of Clinical Trial Participants
  • N43DA-10-2220 - Innovative Diagnostic Drug Screening Tests for Drugs of Abuse
  • N43DA-10-5555 - Tools to Promote Security and Appropriate Prescribing of Scheduled Prescription Drugs
  • N43DA-10-5556 - Marketing Evidence-Based Prevention Interventions for Substance Abuse Prevention
  • N43DA-10-5558 - Development of State-of-the-Art Mechanisms for Epidemiological Records
  • N43DA-10-5559 - Using Handheld Devices to Support Recovery
  • N43DA-10-7774 - Rapid and Sensitive Method for the Determination of Nicotine & its Major Metabolites Cotinine and trans-3'-hydroxycotinine, in Biological Fluids: A Personalized Medicine Approach for Smoking Cessation
  • N43DA-10-7776 - Development of Alternate Drug Delivery Dosage Forms for Drug Abuse Studies

CTN-Related Review Activities

The Protocol Monitoring Board met May 7, 2009 to discuss study proposal CTN 0046, Smoking-Cessation and Stimulant Treatment (S-CAST): Evaluation of the Impact of Concurrent Outpatient Smoking-Cessation and Stimulant Treatment on Stimulant-Dependence Outcomes.

The Data and Safety Monitoring Board(s) met:

  • May 5, 2009, to discuss the progress of study protocol 0032, HIV Rapid Testing and Counseling in Drug Abuse Treatment Programs in the U.S.
  • May 26, 2009 to discuss study proposal CTN 0037, Exercise as a Treatment for Substance Use Disorders.
  • June 8, 2009, to discuss study proposal CTN 0044, Web-delivery of Evidence-Based, Psychosocial Treatment for Substance Use Disorders.

Certificates of Confidentiality

Between March 7, 2009 and August 10, 2009, OEA processed 125 Certificate of Confidentiality applications, including 29 amendments for either extension of expiration date or protocol change.


Index

Research Findings

Program Activities

Extramural Policy and Review Activities

Congressional Affairs

International Activities

Meetings and Conferences

Media and Education Activities

Planned Meetings

Publications

Staff Highlights

Grantee Honors



Archive Home | Accessibility | Privacy | FOIA (NIH) | Current NIDA Home Page
National Institutes of Health logo_Department of Health and Human Services Logo The National Institute on Drug Abuse (NIDA) is part of the National Institutes of Health (NIH) , a component of the U.S. Department of Health and Human Services. Questions? See our Contact Information. . The U.S. government's official web portal